Released May 11, 2026, after the close
10-Q filed May 11, 2026, 41 days after period end · 0001493152-26-022276
Q1 2026 · 10-Q
Revenue—
Net Income-$5.51M-$5.51M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$6.95-$6.95 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$5,590,000N/M
Operating Cash Flow-$2,264,000N/M
Free Cash Flowderived-$2,266,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | — | — | $47.00K | $0.00 |
| Net Income | -$5.51M | -$8.20M | -$6.65M | -$5.42M |
| EPS Diluted | -$6.95 | -$57.76 | -$1.23 | -$1.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR